{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:28:51Z","timestamp":1760783331058,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ccm.2010.06.006","type":"journal-article","created":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T04:13:33Z","timestamp":1288671213000},"page":"707-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors"],"prefix":"10.1016","volume":"31","author":[{"given":"Timothy A.","family":"Morris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2010.06.006_bib1","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1046\/j.1538-7836.2003.00270.x","article-title":"Heparin-induced thrombocytopenia","volume":"1","author":"Chong","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib2","first-page":"7","article-title":"Antigens involved in heparin-induced thrombocytopenia","volume":"36","author":"Amiral","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ccm.2010.06.006_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2141.1999.01717.x","article-title":"Further characterization of antibody and antigen in heparin-induced thrombocytopenia","volume":"107","author":"Newman","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ccm.2010.06.006_bib4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2141.2000.02034.x","article-title":"Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation","volume":"109","author":"Amiral","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ccm.2010.06.006_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/09537100075751","article-title":"Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia","volume":"11","author":"Horsewood","year":"2000","journal-title":"Platelets"},{"issue":"Suppl\u00a01","key":"10.1016\/j.ccm.2010.06.006_bib6","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1177\/10760296990050S107","article-title":"Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome","volume":"5","author":"Ahmad","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib7","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood.V92.9.3250","article-title":"Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia","volume":"92","author":"Ziporen","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2010.06.006_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2141.1996.d01-1876.x","article-title":"The epitope specificity of heparin-induced thrombocytopenia","volume":"95","author":"Horsewood","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ccm.2010.06.006_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.1997.4183225.x","article-title":"Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium","volume":"99","author":"Pouplard","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ccm.2010.06.006_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0022-2143(96)90060-8","article-title":"Platelet binding of IgG from patients with heparin-induced thrombocytopenia","volume":"127","author":"Horne","year":"1996","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1378\/chest.06-2518","article-title":"No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a meta-analysis","volume":"132","author":"Morris","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2010.06.006_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0002-9343(99)00124-2","article-title":"Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia","volume":"106","author":"Wallis","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib13","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2010.06.006_bib14","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","article-title":"The separation of active and inactive forms of heparin","volume":"69","author":"Lam","year":"1976","journal-title":"Biochem Biophys Res Commun JID \u20130372516"},{"issue":"Suppl","key":"10.1016\/j.ccm.2010.06.006_bib16","first-page":"12","article-title":"Pharmacology of low molecular weight heparins","volume":"16","author":"Harenberg","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib17","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1016\/S0021-9258(18)42309-5","article-title":"Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement","volume":"267","author":"Olson","year":"1992","journal-title":"J\u00a0Biol Chem JID \u20132985121R"},{"key":"10.1016\/j.ccm.2010.06.006_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-0038-1646603","article-title":"The action of a synthetic pentasaccharide on thrombin generation in whole plasma","volume":"61","author":"Beguin","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib19","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2010.06.006_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V79.1.1.1","article-title":"Low molecular weight heparin","volume":"79","author":"Hirsh","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2010.06.006_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.thromres.2004.07.010","article-title":"Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity","volume":"115","author":"Morris","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.ccm.2010.06.006_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.296.8.935","article-title":"Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism","volume":"296","author":"Kearon","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2010.06.006_bib23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N\u00a0Engl J Med JID \u20130255562"},{"key":"10.1016\/j.ccm.2010.06.006_bib24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib25","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet JID \u20132985213R"},{"key":"10.1016\/j.ccm.2010.06.006_bib26","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet JID \u20132985213R"},{"key":"10.1016\/j.ccm.2010.06.006_bib27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study","volume":"163","author":"Eriksson","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib28","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib29","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib30","unstructured":"Prescribing label for ARIXTRA, NDA no. 021345. Approved 12\/23\/2009, in Administration FaD (ed), 2009."},{"key":"10.1016\/j.ccm.2010.06.006_bib31","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)","volume":"99","author":"Rota","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","article-title":"Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux)","volume":"109","author":"Samama","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.ccm.2010.06.006_bib34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib35","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccm.2010.06.006_bib36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2010.03746.x","article-title":"Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion","volume":"8","author":"Paty","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib37","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ccm.2010.06.006_bib38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2010.06.006_bib39","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1016\/j.ccm.2010.06.006_bib41","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib43","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ccm.2010.06.006_bib44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2014an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ccm.2010.06.006_bib47","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2010.06.006_bib49","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2010.06.006_bib51","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A\u00a0dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2010.06.006_bib52","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2007","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ccm.2010.06.006_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ccm.2010.06.006_bib54","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2010.06.006_bib55","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study","volume":"6","author":"Buller","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccm.2010.06.006_bib56","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-meth oxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ccm.2010.06.006_bib57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A\u00a0randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523110000808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523110000808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:46:11Z","timestamp":1759452371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523110000808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0272523110000808"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2010.06.006","relation":{},"ISSN":["0272-5231"],"issn-type":[{"type":"print","value":"0272-5231"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2010.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}